


JOINT PROGRAMMING INITIATIVE ON ANTIMICROBIAL RESISTANCE





# JPIAMR'S ADDED VALUE





# WORKING TOGETHER

ARGENTINA CANADA BELGIUM **CZECH REPUBLIC** DENMARK **ESTONIA** FINLAND FRANCE GERMANY GREECE ISRAEL ITALY JAPAN THE NETHERLANDS NORWAY POLAND ROMANIA SPAIN **SWEDEN** SWITZERLAND TURKEY THE UNITED KINGDOM

#### **22 COUNTRIES** TO DATE HAVE JOINED FORCES TO DEFINE A COMMON VISION

22 countries to date have joined forces to define a common vision, a strategic research agenda and joint planning as well as implementation of national research programmes

**O** jpiamr

# STRATEGIC RESEARCH AGENDA (SRA)

**1.** Development of novel antibiotics and alternatives for antibiotics - from basic research to the market.

**2.** Design strategies to improve treatment and prevention of infections by developing new diagnostics.

#### SURVEILLANCE

DIAGNOSTICS

**ENVIRONMENT** 

**3.** Standardisation and extension of surveillance systems to establish a global surveillance programme on antibiotic resistance and antibiotic use.

#### TRANSMISSION

**4.** To understand the Transmission dynamics and to develop evidence-based strategies to minimise the spread of resistance

**5.** The role of the environment as a source for the selection and spread.

INTERVENTIONS

THERAPEUTICS

**6.** Designing and testing interventions to prevent acquisition, transmission and infection caused by AMR.



# ACTIVITIES

## DEVELOPING INTERNATIONAL COLLABORATION

#### THE WORLD HEALTH ORGANISATION (WHO)

- AMR Global Research Agenda
- WHO is an observer on the JPIAMR Management Board

#### G7

- Working closely on the elaboration and implementation of the AMR Declaration

Transatlantic US-EU Task Force on AMR (TATFAR)

Joint Industry Group EC-JPI-IMI-EFPIA



# ACTIVITIES



## EXPLORATORY / SCOPING WORKSHOPS

- Information Systems, Feb 2015
- Diagnostics, May 2015
- Research Infrastructures, Oct 2015
- Transmission Dynamics, Oct 2015
- Intergovernmental Collaboration, Nov 2015
- New Frontiers in Antibacterial Resistance Research, Jan 2016
- Surveillance, Oct 2016

. . .

- New Antibiotics, Dec 2016
- TO IDENTIFY FUTURE JOINT ACTIONS
- TO MAP THE LANDSCAPE AND IDENTIFY KNOWLEDGE GAPS
- TO BRING TOGETHER EXPERTS FROM DIVERSE FIELDS



# ACTIVITIES

## CALLS FOR RESEARCH PROPOSALS

- ANNUAL JOINT CALLS WITH FUNDING AGENCIES Every January



## JPIAMR's First Joint Call (launched January 2014)

Focus of Call	InnovaResistance: Innovative approaches to address antibacterial resistance	
Number of countries	12	
Total funding	13,8M€ awarded 8,2M€	
Funding term	3 years (2014-15 to 2017-18)	
Number of applications	40	
Number of teams funded	7	
Notes	<ul> <li>Largest global initiative on AMR to date</li> <li>Nominated projects cover areas within prevention of infection, treatment (therapy) development, drug development, target identification for antibacterial drug development, and pharmacokinetics</li> </ul>	



## JPIAMR's Second Joint Call (launched May 2015)

Focus of Call	Repurposing of neglected antibiotics and characterizing antibiotics or antibiotic and nonantibiotic combinations	
Number of countries	9	
Total funding	9,65M€ awarded 4,45M€	
Funding term	Up to 3 years, starting late 2015/early 2016	
Number of applications	16	
Number of teams funded	3	
Notes	<ul> <li>Goal is to sustain defense against AMR by reviving Neglected and Disused Antibiotics (ND-AB), designing combinations of ND-AB and antibiotic and also designing combinations of ND-AB and non-antibiotic in order to reduce occurrence of resistance or overcome established resistance.</li> </ul>	



Funded projects in JPIAMR therapeutics area: JPIAMR funds 10 projects with total funding of 12,6 M Euros with partners from 12 different countries in call 2014 and 2015

Area	Projects	Total budget (Euro)
Strategies to inhibit or reduce the acquisition of resistance	noTBsec, NPERDMDR, SENIBOTAR	3 278 101
New bacterial targets and/or therapeutic compounds	NAPCLI	1 424 062
Novel therapies to overcome known antimicrobial resistance mechanisms and restore susceptibility to conventional antibiotics	DesInMBL, REBEL	1 654 385
Re-evaluation of existing anti- microbial compounds	EVOBIOTIC	1 756 291
Repurposing of neglected antibiotics and characterizing antibiotics or antibiotic and non- antibiotic combinations to overcome bacterial antibiotic resistance	ABIMMUNE, CO-ACTION, COMBINATORIALS	4 544 624
TOTAL		12,6

.eu

## ONGOING FIRST EVER CALL ON AMR TRANSMISSION DYNAMICS JPI-EC-AMR COFUND CALL OPEN 18 JAN 2016 – Pre-proposals MARCH 2016

To unravel dynamics of transmission and selection of AMR at genetic, bacterial, animal, human, societal, and environmental levels, in order to design and evaluate preventive and intervening measures for controlling resistance.



YEAR OF CALL CLOSURE: **2016** 



NUMBER OF PARTICIPATING COUNTRIES: **17** 



TOTAL CALL BUDGET: APROX **28 M EUR** 



EUROPEAN COMMISSION CONTRIBUTION: APROX **7 M EUR** 

# TOTAL: OVER 30 M EUR



# JPI AMR - 3<sup>rd</sup> call – Transmission dynamics

#### 83 projects submitted Requesting 118 M€

38 kept after evaluation step 1

**O** jpiamr

Funding Organisation	Results	
Medical Research Council (MRC), UK	IN	
	OUT	22
Federal Ministry of Education and Research (BMBF), Germany	IN	19
	OUT	18
French National Research Agency (ANR), France	IN	14
	OUT	14
Zorgonderzoek Nederland (ZON), The Netherlands	IN	12
	OUT	13
Swedish Research Council (SRC), Sweden	IN	10
	OUT	7
Canadian Institutes of Health Research (CIHR), Canada	IN	9
	OUT	9
The Research Council of Norway (RCN), Norway	IN	8
	OUT	9
Foundation for Science and Technology (FCT), Portugal	IN	8
	OUT	9
Innovationsfonden (DIF), Denmark	IN	8
	OUT	13
Ministerio de Economia y Competetividad (MINECO), Spain	IN	7
	OUT	13
National Institute of Health Carlos III (ISCIII), Spain	IN	7
	OUT	9
Swedish Research Council Formas, Sweden	IN	5
	OUT	3
Swiss National Science Foundation (SNSF), Switzerland	IN	5
	OUT	9
Narodowe Centrum Nauki (NCN), Poland	IN	4
	OUT	4
Italian Ministry of Health (MoH), Italy	IN	2
	OUT	6
National Authority for Scientific Research and Innovation, Romania	IN	2
	OUT	5
Research Foundation Flanders (FWO), Belgium, Flanders	OUT	4
Chief Scientist Office of the Ministry of Health (CSO-MOH), Israel	IN	1
	OUT	4
Scientific and Technological Research Council of Turkey (TÜBITAK), Turkey	IN	1
	OUT	3
State Education Development Agency (VIAA), Latvia	IN	1
	OUT	1
Fund for Scientific Research - FNRS (F.R.SFNRS), Belgium, French-speakin	g OUT	3
Other	IN	1
	OUT	6

Number of Projects

#### ONGOING

# CALL ON AMR TRANSNATIONAL NETWORKS/WORKING GROUPS

A rapid-action call for leading scientists in the AMR field to establish networks that will develop guidelines and/or best practice frameworks. The supported networks will provide outputs within a timeframe of 6-12 months. The outcome is expected to act as a reference point for the wider AMR research community in planning/delivering future research studies



CALL CLOSURE: 6June 2016



NUMBER OF PARTICIPATING COUNTRIES: **10** 



BUDGET PER PROJECT: APROX 50,000EUR



PROJECT LENGTH: APROX **1 YEAR** 

# TOTAL: OVER 650 K€ EUR expectations to fund 10-13 networks



## JPI AMR - 4th call - Networks/ Working groups

- Guidelines on use (Human & Veterinary) Affordable stewardship
- Surveillance in primary care
- New anti-infective/ New adjuvant therapies / Alternative approaches
- Evaluation of risk for generation of resistance in human setting
- Rapid diagnostic tests
- Role of environmental factors
- Infrastructures/Biobanks available relevant to infection and AMR

Funding dedicated to meetings/ Workshops/ brainstorming sessions

Expected output:

"white papers", strategies, prospective analysis, guidelines



# CALL ON AMR RESEARCH NETWORKS

### 20 proposal received : 209 teams involved



#### www.jpiamr.eu

#### **O** jpiamr

NEXT

# JPI AMR - 5th call - INTERVENTIONS NEXT CALL JANUARY 2017 CALL ON AMR INTERVENTIONS

- Large scale multi-center studies of different intervention strategies designed to prevent AMR infections in hospitals using a cluster-randomized design to find the most valuable ones. (Clinical outcome). Comparison of bundles of AMR prevention and control strategies in controlled cost-efficacy trials (in health care, agricultural, environmental settings).





## JOINT PROGRAMMING INITIATIVE ON ANTIMICROBIAL RESISTANCE

Contact us Secretariat.jpiamr@vr.se

